The Market for Needle-Free Drug Delivery Systems

   Single User - $3,500
   Site License (one location, 10 users) - $4,570
   Corporate License - $7,000

Published Jul 14, 2016 | 160 Pages | Pub ID: KLI15055265

The Market for Needle-Free Drug Delivery Systems

This report, Needle-Free Drug Delivery, details the types of drug delivery systems and technologies that are being used in 2016, as well as those that may become major market factors by the end of the forecast period. The report describes the industry, its relationship to various healthcare channels, and the trends for the future.

Needle-free jet injection devices can and should play a major role in solving the problems of needle-stick injuries and needle phobia in the United States. However, the needle-free jet injector industry is struggling to overcome significant obstacles in this country and abroad before these devices become widely accepted and used for administering drugs and especially vaccines. Specific trends and demographics are influencing growth of the needle-free drug delivery market. A significant influence is the growth in the elderly population. Ease of administration, frequency of administration, safety, and cost are of major importance to all consumers especially the elderly population. Needle-free drug delivery methods help to meet those needs for efficacy, safety, patient compliance, and ease of use.

As part of its extensive coverage, this report provide the following information:
  • Market Estimate and Forecast by Technology (Jet, Other)
  • Market Estimate and Forecast by Application (Insulin, Vaccine, Pediatric, Pain, Other )
  • Needle-Free Products on the Market
  • Cost per Million Injections by Injector Type
  • Seven Important Conclusions About the Market
  • Profiles of Injectable/Implantable and Needle-Free Drug Delivery Companies

Vaccine administration is a focal point of needle-free drug delivery. Providing the needed vaccines in remote areas where there are limited healthcare personnel is a goal of needle-free vaccine administration. In addition, the use of needle-free technology in the pediatric population is becoming an increasingly useful method of delivery for children, who generally require many vaccines in the early years. One of the most significant drivers of the needle-free drug delivery market is the rise in the number of biopharmaceuticals. Biopharmaceuticals have shown great promise in treating various diseases and are considered standard of care in some cases. However, most biologics are administered by injection. Needle-free administration provides a cost-effective, easy to use, safe method to administer biologics without the need for traditional injection apparatus or trained personnel.

Most needle-free jet injectors use metal springs, compressed air, or CO2 gas to power the injection. The device's nozzle is held against the patient's skin and once activated, the device injects a fine stream of the vaccine or drug at a high pressure into the skin. The most common orifice size is 0.127 mm, whereas that of a 25-gauge needle is 1 mm.. Companies are developing a new generation of sophisticated delivery systems. Targeted delivery has already advanced with new polymer-based chemotherapy implants.The geographic scope of the report is worldwide. Numbers provided in this report represent global market sizes and revenues with no regional breakout. In terms of products, the report includes data on needle-free injection delivery and implantable delivery, which includes sustained release delivery and targeted delivery systems.

As the discovery and development of new drugs create the promise of relief and improved levels of care for a variety of chronic conditions, developers are increasingly aware of the need to pair these promising new therapies, more than half of which cannot be taken orally, with delivery methods that are patient-friendly and that encourage compliance. These combination products, in which the delivery device is an integral part of the approved drug therapy, must take into account the needs of a broad range of end users, including elderly patients and those with compromised dexterity, a rapidly-growing demographic segment of the population in developed countries. For many drug developers, the answer to this challenge will increasingly be needle-free injection. While the concept behind needle-free injection is uncomplicated, it has only been recently, with the convergence of synthetic materials and computerized design software that reliable and cost-effective devices have begun to appear. New designs currently being developed will create new opportunities for needle-free injection.

Companies Covered in this report include:

  • 3M Pharmaceuticals
  • Akra Dermojet
  • Antares Pharma, Inc.
  • Becton Dickinson and Company
  • Bioject Medical Technologies, Inc.
  • Crossject SA
  • D’Antonio Consultants International, Inc
  • Glide Pharma Technologies Limited
  • Injex Pharma AG
  • Inovio Pharmaceuticals, Inc.
  • Medical International technologies, Inc
  • MedImmune, Inc
  • Mystic Pharmaceuticals, Inc
  • National Medical Products, Inc
  • Optinose, Inc
  • Pharmajet, Inc
  • PowderMed, Inc/Pfizer
  • Valeritas, Inc
  • Zogenix, Inc
In this report,  {{key}} appears {{searchResults.reportMatchCounts[value]}} times
We were unable to search inside this report.
No results matched your search criteria.

Search for an exact word or phrase by placing the word or phrase in quotation marks ("market trend"). Search for different versions or tenses of a word by placing an asterisk at the end of the word (pharma*).

Please note that your term must be at least three characters long and numbers will be blocked by the # sign.